Would it surprise you to know that some of the most popular go-to cleaning supplies all derived from a soap that was launched in the late 1800s?
Proctor and Gamble first created its iconic Ivory soap in 1879 and has since created a number of products that people rely on everyday. That first bar of soap was created for use on human skin. A short time after its success, Proctor and Gamble began creating new formulas from the Ivory derivative.
Some of the formulas, which ended up being performance failures due to either a lack of effective cleaning or residue buildup, included Dreft and Dash soaps. Tide ultimately replaced both of those options as the superior detergent in 1946.
While the original Tide formula was designed for clothes and dishes, it actually was more suitable for handwashing.
Then, in 1955 when the dishwasher became a prominent household item, Proctor and Gamble went back to their Ivory soap formula to create a new one called Cascade. It has since gone through several changes for optimal dishwashing.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.
